Contemporary results of anatomic radical prostatectomy

Ca-A Cancer Journal for Clinicians

Volumn 49, Issue 5, 1999, Pages 282-296

  Catalona, William J ^a   Ramos, Christian G ^b,c   Carvalhal, Gustavo F ^b,d  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Urologie Surgery

^c HOSPITAL DEL TRABAJADOR   (Chile)

^d PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

CANCER SURGERY; CONTINENCE; LIFE EXPECTANCY; LYMPH NODE METASTASIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; REVIEW; SEXUAL FUNCTION; SURGICAL ANATOMY; SURGICAL MORTALITY; TREATMENT FAILURE;

EID: 0033501247     PISSN: 00079235     EISSN: None     Source Type: Journal    
DOI: 10.3322/canjclin.49.5.282     Document Type: Review

References (61)

1. Landis SH, Murray T, Bolden S, Wingo PA: Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
2. Young HH: The early diagnosis and radical cure of carcinoma of the prostate: Being a study of 40 cases and presentation of a radical operation which was carried out in 4 cases. Bull Johns Hopkins Hosp 1905;16:315-321.
3. Walsh PC, Donker PJ: Impotence following radical prostatectomy: Insight into etiology and prevention. J Urol 1982;128:492-497.
4. Catalona WJ, Carvalhal GF, Mager DE, Smith DS: Potency, continence, and complication rates in 1,870 consecutive radical retropubic prostatectomies. J Urol 1999;162:433-438.
5. Walsh PC, Partin AW, Epstein JI: Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years. J Urol 1994;152:1831-1836.
6. Eastham JA, Scardino, PT: Radical Prostatectomy, in Walsh PC, Retik AB, Vaughan ED Jr, Wein AJ (eds): Campbell's Urology, ed 7. Philadelphia, WB Saunders Company, 1998, pp 2547-2564.
7. Gibbons RP, Correa RJ Jr, Brannen GE, et al: Total prostatectomy for localized prostatic cancer. J Urol 1984;131:73-76.
8. Paulson DF: Impact of radical prostatectomy in the management of clinically localized disease. J Urol 1994;152:1826-1830.
9. Carlin BI, Resnick MI: Anatomic approach to radical perineal prostatectomy. Urol Clin North Amer 1995;22:461-73.
10. Catalona WJ, Smith DS, Ratliff TL, et al: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61.
11. Lu-Yao GL, Friedman M, Yao SL: Use of radical prostatectomy among Medicare beneficiaries before and after the introduction of prostate specific antigen testing. J Urol 1997;157:2219-2222.
12. Zelefsky MJ, Leibel SA, Gaudin PB, et al: Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 1998;41:491-500.
13. Almroth A, Ljung G, Eklund T, et al: Value of sextant biopsies in the assessment of local cure following external beam radiotherapy of prostatic adenocarcinoma. Scand J Urol Nephrol 1998;32:111-115.
14. Ragde H, Elgamal AA, Snow PB, et al: Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer 1998;83:989-1001.
15. D'Amico AV, Whittington R, Malkowicz SB, et al: Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280:969-974.
16. Cohen JK, Miller R, Benoit R, et al: Five year outcomes of PSA and biopsy following cryosurgery as primary treatment for localized prostate cancer. J Urol 1998;159:252 (abstract 967).
17. Albertsen PC, Hanley JA, Gleason DF, Barry MJ: Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280:975-980.
18. Johansson JE, Holmberg L, Johansson S, et al: Fifteen-year survival in prostate cancer: A prospective, population-based study in Sweden. JAMA 1997;277:467-471.
19. Catalona WJ, Smith DS: Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: Intermediate-term results. J Urol 1998;160:2428-2434.
20. Ventura SJ, Peters KD, Martin JA, Maurer JD: Births and deaths: United States, 1996. Mon Vital Stat Rep 1997;46 (1 Suppl 2):1-40.
21. Epstein JI, Walsh PC, Carmichael M, Brendler CB: Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994;271:368-374.
22. Stein A, deKernion JB, Smith RB, et al: Prostate specific antigen levels after radical prostatectomy in patients with organ confined and locally extensive prostate cancer. J Urol 1992;147:942-946.
23. Zincke H, Oesterling JE, Blute ML, et al: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994;152:1850-1857.
24. Pound CR, Partin AW, Epstein JI, Walsh PC: Prostate-specific antigen after anatomic radical retropubic prostatectomy: Patterns of recurrence and cancer control. Urol Clin North Amer 1997;24:395-406.
25. Smith DS, Catalona WJ: The nature of prostate cancer detected through prostate specific antigen based screening. J Urol 1994;152:1732-1736.
26. Oefelein MG, Smith ND, Grayhack JT, et al: Long-term results of radical retropubic prostatectomy in men with high grade carcinoma of the prostate. J Urol 1997;158:1460-65.
27. Krongrad A, Lai H, Lai S: Survival after radical prostatectomy. JAMA 1997;278:44-46.
28. Roach M III, Lu J, Pilepich MV, et al: Long term survival in 1500 men treated for prostate cancer with radiotherapy alone: Radiation therapy oncology group (RTOG) protocols 7706, 7506, 8531, and 8610. J Urol 1998;159:219 (abstract 845).
29. Abbas F, Kattan MW, Wheeler TM, et al: Survival and cancer control for patients with cT1-T2 prostate cancer with intent to treat by radical prostatectomy. J Urol 1998;159:252 (abstract 964).
30. Fowler FJ Jr, Barry MJ, Lu-Yao G, et al: Patient-reported complications and follow-up treatment after radical prostatectomy: The National Medicare Experience: 1988-1990 (Updated June 1993). Urology 1993;42:622-629.
31. Fowler FJ Jr, Barry MJ, Lu-Yao G, et al: Effect of radical prostatectomy for prostate cancer on patient quality of life: Results from a Medicare survey. Urology 1995;45:1007-1015.
32. Litwin MS, Hays RD, Fink A, et al: Quality-of-life outcomes in men treated for localized prostate cancer. JAMA 1995;273:129-135.
33. Eastham JA, Kattan MW, Rogers E, et al: Risk factors for urinary incontinence after radical prostatectomy. J Urol 1996;156:1707-1713.
34. Steiner MS, Morton RA, Walsh PC: Impact of anatomical radical prostatectomy on urinary continence. J Urol 1991;145:512-515.
35. Geary ES, Dendinger TE, Freiha FS, Stamey TA: Incontinence and vesical neck strictures following radical retropubic prostatectomy. Urology 1995;45:1000-1006.
36. Weldon VE, Tavel FR, Neuwirth H: Continence, potency and morbidity after radical perineal prostatectomy. J Urol 1997:158:1470-1475.
37. Gaylis FD, Friedel WE, Armas OA: Radical retropubic prostatectomy outcomes at a community hospital. J Urol 1998;159:167-171.
38. Talcott JA, Rieker P, Propert KJ, et al: Patient-reported impotence and incontinence after nerve-sparing radical prostatectomy. Natl Cancer Inst 1997:89:1117-1123.
39. Mettlin CJ, Murphy GP, Sylvester J, et al: Results of hospital cancer registry surveys by the American College of Surgeons: Outcomes of prostate cancer treatment by radical prostatectomy. Cancer 1997;80:1875-1881.
40. Montorsi F, Guazzoni G, Strambi LF, et al: Recovery of spontaneous erectile function after nerve-sparing radical retropubic prostatectomy with and without early intracavernous injections of alprostadil: Results of a prospective; randomized trial. J Urol 1997;158:1408-1410.
41. Frazier HA, Robertson JE, Paulson DF: Radical prostatectomy: The pros and cons of the perineal versus retropubic approach. J Urol 1992;147:888-890.
42. Litwiller SE, Reisch J, Roehrborn CG: Risk factors for impotence following radical prostatectomy: analysis in a community practice. J Urol 1998; 159:219 (abstract 848).
43. Geary ES, Dendinger TE, Freiha FS, Stamey TA: Nerve sparing radical prostatectomy. A different view. J Urol 1995;154:145-149.
44. Licht MR, Klein EA: Early hospital discharge after radical retropubic prostatectomy: Impact on cost and complication rate. Urology 1994;44:700-704.
45. Lerner SE, Blute ML, Zincke H: Critical evaluation of salvage surgery for radio-recurrent/resistant prostate cancer. J Urol 1995;154:1103-1109.
46. Abbas F, Kaplan M, Soloway MS: Induction androgen deprivation therapy before radical prostatectomy for prostate cancer: Initial results. Br J Urol 1996;77:423-428.
47. Fair WR, Cookson MS, Stroumbakis N, et al: The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology 1997;49(3A Suppl):46-55.
48. Cadeddu JA, Partin AW, Epstein JI, Walsh PC: Stage D1 (T1-3, N1-3, MO) prostate cancer: A case-controlled comparison of conservative treatment versus radical prostatectomy. Urology 1997;50:251-255.
49. Haymana JA, Wang S, McLaughlin PW, et al: 3-dimensional conformal radiation therapy following radical prostatectomy for prostate cancer. J Urol 1998;159:64 (abstract 238).
50. Newhall PM, Iselin CE, Asian P, et al: Prognostic factors of PSA failure after radiation therapy following radical prostatectomy for prostate cancer. J Urol 1998;64 (abstract 241).
51. McCarthy JF, Catalona WJ, Hudson MA: Effect of radiation therapy on detectable serum prostate specific antigen levels following radical prostatectomy: Early versus delayed treatment. J Urol 1994;151:1575-8.
52. D'Amico AV, Whittington R, Malkowicz SB, et al: Prostate-specific antigen failure despite pathologically organ-confined and margin-negative prostate cancer: The basis for an adjuvant therapy trial. J Clin Oncol. 1997;15:1465-1469
53. Rogers E, Ohori M, Kassabian VS, et al: Salvage radical prostatectomy: Outcome measured by serum prostate specific antigen levels. J Urol 1995;153:104-110.
54. Catalona WJ: Radical surgery for advanced prostate cancer and for radiation failures. J Urol 1992;147:916.
55. Byar DP, Corle DK: VACURG randomised trial of radical prostatectomy for stages I and II prostatic cancer: Veterans Administration Cooperative Urological Research Group. Urology 1981;17(4 Suppl):7-11.
56. Paulson DF: Randomized series of treatment with surgery versus radiation for prostate adenocarcinoma. NCI Monogr 1988;7:127-131.
57. Lu-Yao GL, Yao S-L: Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 1997;349:906-910.
58. Chodak GW: Prostate cancer. Lancet 1997; 349:1551.
59. Ohori M, Goad JR, Wheeler TM, et al: Can radical prostatectomy alter the progression of poorly differentiated prostate cancer? J Urol 1994; 152:1843-1849.
60. Partin AW, Lee BR, Carmichael M, et al: Radical prostatectomy for high grade disease: A reevaluation 1994. J Urol 1994;151:1583-1586.
61. Catalona WJ, Smith DS, Ratliff TL, et al: Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1992;270:948-954.